These findings indicated that the ERBB signaling pathway may also contribute to oncogenic HIF2α accumulation in ccRCC, and ERBB receptor inhibitor afatinib may exhibit a more significant therapeutic effect on ccRCC, which may be helpful for patient selection in clinical trials. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.